← Russell 3000 cross-section

RVTY REVVITY, INC.

Trailing twelve months to 2026-07-05 · as filed 2026-08-11, not restated
Healthcare

Scale

Market cap
$14.3bn
Revenue TTM
$2.9bn
Net income TTM
$238m
Free cash flow
$558m
Composite score
43.6
Sector rank
#553

Valuation

P / E
60.4
EV / EBITDA
20.7
EV / sales
5.5
FCF yield
3.89%
Earnings yield vs 10-yr
-3.07pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
8.2%
EBITDA margin
26.5%
ROE
3.3%
ROIC
4.1%
Revenue growth
4.0%

Insider activity, last 90 days

Net open-market
$-0.01m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Consolidated Results of Continuing Operations Revenue Revenue for the three months ended July 5, 2026 was $729.7 million, as compared to $720.3 million for the three months ended June 29, 2025, an increase of $9.4 million, or 1%. Life Sciences segment revenue was $358.7 million for the three months ended July 5, 2026, as compared to $365.9 million for the three months ended June 29, 2025, a decrease of $7.2 million, or 2%, driven by a decrease of $10.2 million in Software revenue, partially offset by an increase of $3.0 million in Life Sciences Solutions revenue. …REVVITY, INC., 10-Q, period ended 2026-07-05, filed 2026-08-11

Read the full passage →